May 6, 2019, NEW YORK—For people with depression, gastrointestinal distress is a common additional burden, and a new study suggests that for some, the two conditions arise from the same glitch in neuron chemistry—low serotonin.
The study, conducted in mice, shows that a shortage of serotonin in the neurons of the gut can cause constipation, just as a serotonin shortage in the brain can lead to depression.
The study also found that a treatment that raises serotonin in the gut and the brain may alleviate both conditions.
Up to a third of people with depression have chronic constipation, and a few studies report that people with depression rate their accompanying bowel difficulties as one of the biggest factors reducing their quality of life.
Severe constipation can obstruct the GI tract and cause serious pain. The condition leads to 2.5 million physician visits and 100,000 hospitalizations each year.
Though some antidepressants are known to cause constipation, medication side effects do not explain all cases.
“Ultimately, many patients with depression are faced with limited treatment options and have to suffer with prominent GI dysfunction,” says study leader Kara Gross Margolis, MD, associate professor of pediatrics at Columbia University Vagelos College of Physicians and Surgeon.
Similarities between the gut and the brain suggest the two conditions may also share a common cause.
“The gut is often called the body’s ‘second brain,’” says Margolis. “It contains more neurons than the spinal cord and uses many of the same neurotransmitters as the brain. So it shouldn’t be surprising that the two conditions could be caused by the same process.”
Because low levels of serotonin in the brain have been linked to depression and serotonin is also used by neurons in the gut, the researchers studied mice to determine if a serotonin shortage also plays a role in constipation.
The mice used in the study carry a genetic mutation (linked to severe depression in people) that impairs the ability of neurons in the brain and the gut to make serotonin.
The serotonin shortage in the gut, the researchers found, reduced the number of neurons in the gut, led to a deterioration of the gut’s lining, and slowed the movement of contents through the GI tract.
“Basically, the mice were constipated,” Margolis says, “and they showed the same kind of GI changes we see in people with constipation.” (In previous studies, these same mice also showed depressive symptoms).
Encouragingly, an experimental drug treatment invented by two of the study’s co-authors, Marc Caron, PhD, and Jacob Jacobsen, PhD, of Duke University, raised serotonin levels in the gut’s neurons and alleviated constipation in the mice.
The treatment—slow-release drug-delivery of 5-HTP, a precursor of serotonin—works in part by increasing the number of GI neurons in adult mice.
The discovery of this connection between a brain and a gastrointestinal disorder suggests that new 5-HTP slow-release therapies could treat related brain-gut conditions simultaneously.
The study is also one of the first to show that neurogenesis in the gut is possible and can correct abnormalities in the gut. “Though it’s been known for many years that neurogenesis occurs in certain parts of the brain, the idea that it occurs in the gut nervous system is relatively new,” Margolis says.
Neurogenesis may help treat other types of constipation. “We see a reduction of neurons in the GI tract with age, and that loss is thought to be a cause of constipation in the elderly,” Margolis says. “The idea that we may be able to use slow-release 5-HTP to treat conditions that require the development of new neurons in the gut may open a whole new avenue of treatment.”
An immediate-release version of 5-HTP is available as a supplement, but it has not been proved scientifically to work and physiologically it should not, as it is too short-acting, Margolis says. 5-HTP is the immediate precursor to serotonin. Once ingested, 5-HTP is converted to serotonin, but the serotonin is rapidly inactivated before it can work effectively.
The slow-release version of 5-HTP used in the current study produces constant administration of 5-HTP which has been demonstrated to remedy the limitations of currently available immediate-release 5-HTP.
Clinical studies are already planned for testing a slow-release 5-HTP drug in people with treatment-resistant depression.
Planning for testing a slow-release 5-HTP drug in constipation is in progress.
The study, titled “Effects of Neuronal Serotonin and Slow-Release 5-HTP on Gastrointestinal Motility in a Mouse Model of Depression,” was published in Gastroenterology.
Additional authors: Narek Israelyan (Columbia University Irving Medical Center), Andrew Del Colle (CUIMC), Zhishan Li (CUIMC, Yeji Park (CUIMC), Albert Xing (CUIMC), Ruth Ann Luna (Baylor College of Medicine, Dane D. Jensen (CUIMC), Moneek Madra (CUIMC), Virginia Saurman (CUIMC), Ray Rahim (CUIMC), Rocco Latorre (CUIMC), Kimberly Law (CUIMC), William Carson (Duke University), and Nigel W. Bunnett (CUIMC).
This work was supported by the National Institutes of Health (NIH grants DK093786,NS15547,MH79201,T35AG044303,NS102722,DE026806, and DK118971); U.S. Department of Defense (grants PR160365 and PR170507); AGA Student Research Fellowship Award; Lundbeck Foundation, and gifts from the Phyllis and Ivan Seidenberg Family Fund for Children’s Digestive Health and The Lennon Family.
Jacob Jacobsen and Marc Caron are inventors on US patents pertaining to slow-release 5-HTP and hold equity in Evecxia Therapeutics, a company founded to develop a slow-release 5-HTP drugs for the management of serotonin-related disorders. Kara Margolis, Jacob Jacobsen, and Marc Caron are inventors on a pending patent application for slow-release 5-HTP treatments for constipation disorders.
###
Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the Vagelos College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cuimc.columbia.edu or columbiadoctors.org.
Enhanced primary care helps reduce ER visits October 1, 2020, CHAPEL HILL, NC—Integrating primary care services and behavioral health services appears to reduce emergency room visits among people with severe psychiatric conditions such as bipolar disorder, a new study suggests. American researchers, using the customary term “serious mental illness,” noted that individuals with such conditions...
READ MORE
Selena Gomez is no stranger to navigating mental health challenges, from dealing with the emotional burden of lupus to her kidney transplant to bipolar’s depression and anxiety. She’s learned the power of self-care and having the right connections—and how to say “no.” On April 3, 2020, singer and actor Selena Gomez candidly revealed that she...
READ MORE
On the one hand, characters with bipolar can demonstrate that treatment leads to stability. On the other, manic extremes make for better drama. “Surely there is someone out there who will take me for who I am: the good, the bad, the full story of love.” That’s award-winning actor Anne Hathaway as Lexi, prognosticating optimistically...
READ MORE
At-risk kids may have dysregulated coping mechanisms December 1, 2020, RIZE, Turkey—A new study has found distinct psychological features among children at high risk for bipolar disorder due to observable symptoms or family history. The Turkish study compared high-risk kids to children without risk factors. They found the high-risk kids were less likely to suppress...
READ MORE
Very interesting. My mother had very severe depression after colon cancer treatment and a surgery removing most of her large intestine. Depression and psychosis was so severe that ECT and medication finally proved to help. I wonder how much was from the physical deterioration of gut health?
I’m bipolar too and take the 5htp on the market. I’ve been taking it three times a day for twenty years. I haven’t had any bowel problems.
What brands do you take?
I am in Sarasota FL and I’m diagnosed with bipolar disorder. I’m very interested in learning more about the new study on time released 5htp